Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

Congratulations to Vivek Malik who was named a Regeneron Science Talent Search 2025 finalist. Vivek is a student at The ...

Regeneron's CD20xCD3 bispecific antibody for non-Hodgin lymphoma (NHL ... of around a dozen candidates in clinical testing. The new drug joins a clutch of CD20xCD3 bispecifics approved in Europe ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $71.75 billion, has been navigating a complex landscape of opportunities and challenges in recent months. According to ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platformfor the ...